About: Should we screen patients with hematologic malignancies for COVID‐19?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Should we screen patients with hematologic malignancies for COVID‐19? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Should we screen patients with hematologic malignancies for COVID‐19?
Creator	Assi, Tarek Ghosn, Marwan Hanna, Colette Ibrahim, Nathalie Karak, Fadi Khoury-Abboud, Rita-Maria Rassy, Elie Samra, Bachar
Source	Medline; PMC
abstract	The coronavirus disease (COVID‐19) pandemic has posed several challenges to the hematology community to re‐organize the medical care of patients with hematologic malignancies. Whereas the oncology societies favored a more or less conservative approach which considered the possibility of delaying treatment administration on a case‐by‐case basis, the hematology community guidelines were less stringent and recommended adequate individualized regimens. As countries are de‐escalating the lockdown and the medical community is unable to foresee the end of the current outbreak will and whether the pandemic would eventually come back as a seasonal infection, there is interest in screening of patients with hematology malignancies with COVID‐19 instead of limiting access to curative treatments. The rapidly accumulating knowledge about COVID‐19 allows a better understanding of the diagnostic tools that may be potentially used in screening. Herein, we briefly review the pathophysiology of COVID‐19, the rationale of screening of patients with hematologic malignancies, tools for screening, and available guidelines. This article is protected by copyright. All rights reserved.
has issue date	2020-07-19(xsd:dateTime)
bibo:doi	10.1002/hon.2780
bibo:pmid	32779823
has license	no-cc
sha1sum (hex)	826dd0dd934e335629543cb33c58c2c1348b795c
schema:url	https://doi.org/10.1002/hon.2780
resource representing a document's title	Should we screen patients with hematologic malignancies for COVID‐19?
has PubMed Central identifier	PMC7405152
has PubMed identifier	32779823
schema:publication	Hematol Oncol
resource representing a document's body	covid:826dd0dd934e335629543cb33c58c2c1348b795c#body_text
is schema:about of	named entity 'possibility' named entity 'tools' named entity 'disease' named entity 'pandemic' named entity 'hematologic malignancies' named entity 'screening' named entity 'COVID-19' named entity 'tools' named entity 'screening' named entity 'curative' named entity 'care' named entity 'rapidly' named entity 'hematologic malignancies' named entity 'hematology' named entity 'de-escalating' named entity 'COVID-19' named entity 'medical community' named entity 'hematologic malignancies' named entity 'hematologic malignancies' named entity 'pathophysiology' named entity 'oncologists' named entity 'lymphoid' named entity 'immune deficiencies' named entity 'corticoid' named entity 'B-cell' named entity 'chronic lymphocytic leukemia' named entity 'healthcare workers' named entity 'neutropenia' named entity 'alemtuzumab' named entity 'mechanical ventilation' named entity 'innate immune response' named entity 'Hematologic malignancies' named entity 'transmissibility' named entity 'higher risk' named entity 'B-cell' named entity 'NK cells' named entity 'diagnostic tests' named entity 'eosinophils' named entity 'CAR-T' named entity 'COVID-19' named entity 'diagnostic purposes' named entity 'leukemias' named entity 'Middle East Respiratory Syndrome' named entity 'COVID-19' named entity 'chest imaging' named entity 'American College of Radiology' named entity 'lymphopenia' named entity 'cytokine storm' named entity 'RT-PCR' named entity 'COVID-19' named entity 'Corticosteroids' named entity 'ofatumumab' named entity 'rituximab' named entity 'multivariate analysis' named entity 'TGFβ' named entity 'statistically significant' named entity 'oncology' named entity 'hematology' named entity 'hematologic malignancies' named entity 'hematologic malignancy' named entity 'hematologic malignancies' named entity 'neutropenia' named entity 'pneumonia' named entity 'TKI' named entity 'serologic testing' named entity 'acute myeloid leukemia' named entity 'asymptomatic' named entity 'hematologic malignancies' named entity 'COVID-19' named entity 'higher risk' named entity 'lymphomas' named entity 'immune dysregulation' named entity 'COVID-19' named entity 'lung'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software